Skip to content

MAKING BEST PRACTICE, EVERYDAY PRACTICE

FREE accredited digital CPD for health care professionals in South Africa

Accredited by the University of Pretoria

MAKING BEST PRACTICE, EVERYDAY PRACTICE

FREE accredited digital CPD for health care professionals in South Africa

Accredited by the University of Pretoria

Menu

Home
About
All clinical topics
SPECIAL INTEREST GROUPS
- Medical interns and registrars
Contact
ACCESS MY PROFILE

Menu

Home
About
All clinical topics
SPECIAL INTEREST GROUPS
- Medical interns and registrars
Contact
ACCESS MY PROFILE

[denovo_breadcrumbs]

Sharing best practice in diabetes care – Case study 4

Questionnaire

To access this module, please register or login:

Login or Register

Sharing best practice in diabetes care – Case study 4
Sharing best practice in diabetes care – Case study 4

Time limit: 0

Questionnaire Summary

0 of 11 Questions completed

Questions:

Information

You have already completed the questionnaire before. Hence you can not start it again.

Questionnaire is loading…

You must sign in or sign up to start the questionnaire.

You must first complete the following:

Results

Questionnaire complete. Results are being recorded.

Results

0 of 11 Questions answered correctly

Time has elapsed

You have reached 0 of 0 point(s), (0)

Earned Point(s): 0 of 0, (0)
0 Essay(s) Pending (Possible Point(s): 0)

Categories

Not categorized 0%

Regrettably, you have failed to achieve the 70% pass mark required by the accrediting HPCSA.
Please read/watch the module carefully and try once more!
(Only two tries are allowed)
Please note you will no longer receive a fail confirmation email.
Congratulations on successfully completing this FREE CPD module!
- For HPCSA members only: No need to load your certificate on HPCSA, as deNovo Medica uploads these weekly. Please allow 5-10 working days for the CPD activity to reflect on your HPCSA profile
- For non-HPCSA members: The above button allows you to download and print your CPD certificate to submit to your council yourself.
Please note you will no longer receive a pass confirmation email. Your activity automatically downloads on to your deNovo Medica profile.
Visit your profile HERE to find all your CPD certificates and activities completed.

1
2
3
4
5
6
7
8
9
10
11

Current
Review
Answered
Correct
Incorrect

Question 1 of 11
1. Question
1. Which clinical and laboratory findings indicate that Mr PH might have target organ damage?
A. Peripheral neuropathy symptoms
Correct Incorrect Correct answer

B. Microalbuminuri
Correct Incorrect Correct answer

C. Metabolic dysfunction-associated fatty liver disease (MAFLD)
Correct Incorrect Correct answer

D. All of the above
Correct Incorrect Correct answer
Question 2 of 11
2. Question
2. What additional tests can be performed to determine the extent of Mr PH’s diabetes-related complications?
A. Fundoscopy
Correct Incorrect Correct answer

B. Fibrosis-4 score
Correct Incorrect Correct answer

C. Exercise stress test
Correct Incorrect Correct answer

D. All of the above
Correct Incorrect Correct answer
Question 3 of 11
3. Question
3. How would you classify Mr PH’s cardiovascular risk according to the European Society of Cardiology (ESC) 2023 guidelines?
A. Low
Correct Incorrect Correct answer

B. Moderate
Correct Incorrect Correct answer

C. High
Correct Incorrect Correct answer

D. Very high
Correct Incorrect Correct answer
Question 4 of 11
4. Question
4. Which is the most appropriate next step in Mr PH’s diabetes management?
A. Continue current treatment
Correct Incorrect Correct answer

B. Add prandial insulin
Correct Incorrect Correct answer

C. Initiate a GLP-1 receptor agonist (GLP-1RA) or fixed-ratio insulin/GLP-1RA combination
Correct Incorrect Correct answer

D. Add pioglitazone
Correct Incorrect Correct answer
Question 5 of 11
5. Question
5. What factor most favours the use of FRC iGlarLixi rather than discrete basal insulin plus discrete GLP-1RA?
A. Simplicity of administration
Correct Incorrect Correct answer

B. Higher hypoglycaemia risk
Correct Incorrect Correct answer

C. Need for multiple daily injections
Correct Incorrect Correct answer

D. Poor patient compliance
Correct Incorrect Correct answer
Question 6 of 11
6. Question
6. Which of Mr PH’s current medications should be discontinued upon iGlarLixi initiation?
A. Metformin
Correct Incorrect Correct answer

B. Dapagliflozin
Correct Incorrect Correct answer

C. Gliclazide MR
Correct Incorrect Correct answer

D. Vildagliptin
Correct Incorrect Correct answer
Question 7 of 11
7. Question
7. What is the preferred starting dose of iGlarLixi for Mr PH?
A. 10 dose steps of 33/100
Correct Incorrect Correct answer

B. 10 dose steps of 50/100
Correct Incorrect Correct answer

C. 20 dose steps of 50/100
Correct Incorrect Correct answer

D. 20 dose steps of 33/100
Correct Incorrect Correct answer
Question 8 of 11
8. Question
8. What initial side effect is most expected and how should it be addressed?
A. Hypoglycaemia
Correct Incorrect Correct answer

B. Nausea managed with dietary advice
Correct Incorrect Correct answer

C. Injection site rash
Correct Incorrect Correct answer
Question 9 of 11
9. Question
9. When is Mr PH likely to reach maximum dose of iGlarLixi 50/100?
A. At 20 dose steps
Correct Incorrect Correct answer

B. At 40 dose steps
Correct Incorrect Correct answer

C. At 60 dose steps
Correct Incorrect Correct answer

D. No defined limit
Correct Incorrect Correct answer
Question 10 of 11
10. Question
10. Has Mr PH reached target HbA1c?
A. Yes, goal of <7.0% as discussed with his primary care provider has been met
Correct Incorrect Correct answer

B. No, consider rapid insulin
Correct Incorrect Correct answer

C. Yes, consider stopping iGlarLixi
Correct Incorrect Correct answer
Question 11 of 11
11. Question
11. Have we achieved adequate control of Mr PH’s cholesterol?
A. Yes
Correct Incorrect Correct answer

B. No
Correct Incorrect Correct answer

C. Maybe
Correct Incorrect Correct answer

All Rights Reserved 2025 © deNovo Medica (Pty) Ltd in South Africa. The content on this website is intended for healthcare related professionals unless stated otherwise.

Get involved

Become a sponsor Become a medical partner author/reviewer/society

Get involved

Become a sponsor Become a medical partner author/reviewer/society

Login

Accessing this module requires a login. Please enter your credentials below!

Username or Email Address

Password

Remember Me

Lost Your Password?